Skip to main content
  • Sign in
  • Help
BOPA
  • Why join BOPA
  • Pricing
  • Education
    • BOPA Introduction to Cancer Course 2025
    • Courses and eLearning
    • SACT Verification Hub (Passport)
    • Resource Library
    • Cancer Hub
    • Education & Training Standards
    • Let’s Talk About SACT – a BOPA Podcast
  • About BOPA
    • About BOPA
    • Welcome to BOPA
    • Executive Committee
    • Subcommittees & working groups
    • Affiliated Groups
    • Specialist Advisory Groups
    • International Groups
    • BOPA Fellows
    • Corporate Membership
    • BOPA membership FAQs
  • Conference
    • Latest Conference 2025
    • Abstract Submission Opens 31st March
    • Past Symposiums / Conferences
  • News & Events
    • News
    • Events calendar
    • Submit event
  • Menu iconLCC
    • LCC
    • Cancer Hub
  • Join BOPA
Join BOPA
BOPA Join BOPA
  • Why join BOPA
  • Pricing
  • Education
    • BOPA Introduction to Cancer Course 2025
    • Courses and eLearning
    • SACT Verification Hub (Passport)
    • Resource Library
    • Cancer Hub
    • Education & Training Standards
    • Let’s Talk About SACT – a BOPA Podcast
  • About BOPA
    • About BOPA
    • Welcome to BOPA
    • Executive Committee
    • Subcommittees & working groups
    • Affiliated Groups
    • Specialist Advisory Groups
    • International Groups
    • BOPA Fellows
    • Corporate Membership
    • BOPA membership FAQs
  • Conference
    • Latest Conference 2025
    • Abstract Submission Opens 31st March
    • Past Symposiums / Conferences
  • News & Events
    • News
    • Events calendar
    • Submit event
  • Menu iconLCC
    • LCC
    • Cancer Hub
  • Join BOPA

Home » Solid Tumour

Solid Tumour

BOPA encourages its members to share helpful documents that can benefit other members.  BOPA respects the intellectual property of original authors and requires anyone who uses other members’ work to include an acknowledgment of, or reference to, the source in their version.

DISCLAIMER:
BOPA is not the author or owner of some of the documents published on our website.  BOPA as a professional interest group will share documents via its website that are of interest to BOPA members, but has no responsibility for use of the documents and for any recommendations within the documents so members must use these at their discretion. BOPA cannot accept responsibility for any errors or omissions or for any consequences from application of information in the documents attached and make no warranty, expressed or implicit with respect to the contents of this webpage. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site or document(s) downloaded from it.

Posters and abstracts on the BOPA website remain the property of the authors and anyone wishing to reference or share this work must contact the authors directly. Abstracts subsequently published in JOPP follow copyright rules from JOPP.

Last reviewed: 10/07/19 by Katherine bayliss

Pilot Study: Incidence of Hyperbilirubinaemia in Sarcoma Patients Receiving Single Agent Doxorubicin

Abstracts

View resources
Last reviewed: 10/07/19 by Benjamin Thwaites

Assessing the safety of an increase in validity of full blood counts from 72 hours to 96 hours in our breast cancer chemotherapy patients.

Abstracts

View resources
Last reviewed: 10/07/19 by B. Buijtenhuijs

Is the use of GCSF justified in patients receiving Docetaxel for castrate resistant prostate cancer?

Abstracts

View resources
Last reviewed: 10/07/19 by Julie Clarke

New treatments for advanced (unresectable or metastatic) melanoma: what do they mean for patients? Real world experience from NHS Greater Glasgow and Clyde

Abstracts

View resources
Last reviewed: 10/07/19 by Kelly Baillie

How do local demographics influence outcomes for metastatic Castration Resistant Prostate Cancer (mCRPC) patients prescribed abiraterone?

Abstracts

View resources
Last reviewed: 10/07/19 by Hector Mateo-Carrasco

Safety of extended temozolomide regimes in brain tumour patients

Abstracts

View resources
Last reviewed: 10/07/19 by Joseph Williams

Preliminary results of a Specialist Pharmacist led Medicines Optimisation Service (Polypharmacy clinic) for Prostate Cancer patients

Abstracts

View resources
Last reviewed: 10/07/19 by Lillian Cortez

Qualitative analysis of the multidisciplinary acceptability of the introduction of a Band 7 oncology pharmacist into a Breast Cancer Clinic

Abstracts

View resources
Last reviewed: 10/07/19 by Pinkie Chambers

Denosumab Self Administration: A Pilot for Breast Cancer Patients

Abstracts

View resources
Last reviewed: 10/07/19 by Rakesh Mattu

The safety of administering Bortezomib using haematological counts from the day of the previous administration

Abstracts

View resources
Last reviewed: 10/07/19 by Emma Dunlop Corcoran

Quality of life in patients receiving medicines for prostate cancer: What do clinicians think is important?

Abstracts

View resources
Last reviewed: 10/07/19 by Katherine Bayliss

Pilot study: Response rates and incidence of neutropenia in metastatic colorectal patients receiving Lonsurf® (trifluridine-tipiracil)

Abstracts

View resources

Filter for resources

  • Types

  • Tags

  • Reset

Previous 1 2 3 Next
BOPA logo
  • Why join BOPA
  • Pricing/Join
  • Conference 2024
  • Education
  • About
  • News & Events
  • Help
  • Go to LinkedIn
  • Go to Twitter
  • Go to Facebook
  • Go to Instagram
  • Go to Bluesky

© Copyright 2025 British Oncology Pharmacy Association.
Registered Charity No. 1065026

  • Privacy Policy
  • T&Cs Website
  • T&Cs Membership
  • Cookies
  • Contact
Designed and developed by Rouge
Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience when you browse our website and also allows us to improve our site. By continuing to browse the site, you are agreeing to our use of cookies.